Albuterol oral solution
 Albuterol Syrup

drug-information.ru

|Albuterol oral solution Albuterol Syrup

Drugs search, click the first letter of a drug name:


| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9  Home

Albuterol


Generic Name: Albuterol sulfate
Dosage Form: Oral solution

Rx only

Albuterol Description

Albuterol Sulfate Syrup (Oral Solution) contains Albuterol sulfate, USP, the racemic form of Albuterol and a relatively selective beta2-adrenergic bronchodilator. Albuterol sulfate has the chemical name α1-[(tert-butylamino)methyl]-4-hydroxy-m-xylene-α,α"-diol sulfate (2:1) (salt) and the following chemical structure:

Albuterol sulfate is a white or practically white powder freely soluble in water and slightly soluble in alcohol, in chloroform, and in ether per USP definition.

The World Health Organization recommended name for Albuterol base is salbutamol.

Albuterol sulfate syrup (oral solution) for oral administration contains 2 mg of Albuterol as 2.4 mg of Albuterol sulfate in each teaspoonful (5 mL). Albuterol sulfate oral solution also contains the inactive ingredients citric acid, FD&C Yellow #6, hypromellose, purified water, saccharin sodium, sodium benzoate, and strawberry flavor. Albuterol sulfate syrup (oral solution) may contain sodium citrate for pH adjustment. The pH of the oral solution is 3.3 to 4.0.

Albuterol - Clinical Pharmacology

In vitro studies and in vivo pharmacologic studies have demonstrated that Albuterol has a preferential effect on beta2-adrenergic receptors compared with isoproterenol. While it is recognized that beta2-adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta2-receptors in the human heart existing in a concentration between 10% and 50%. The precise function of these receptors has not been established (see WARNINGS).

The pharmacologic effects of beta-adrenergic agonist drugs, including Albuterol, are at least in part attributable to stimulation through beta-adrenergic receptors of intracellular adenyl cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3",5"-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels are associated with relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

Albuterol has been shown in most controlled clinical trials to have more effect on the respiratory tract, in the form of bronchial smooth muscle relaxation, than isoproterenol at comparable doses while producing fewer cardiovascular effects.

Albuterol is longer acting than isoproterenol in most patients by any route of administration because it is not a substrate for the cellular uptake processes for catecholamines nor for catechol-O-methyl transferase.

Preclinical:

Intravenous studies in rats with Albuterol sulfate have demonstrated that Albuterol crosses the blood brain barrier and reaches brain concentrations amounting to approximately 5% of the plasma concentrations. In structures outside the brain barrier (pineal and pituitary glands), Albuterol concentrations were found to be 100 times those in the whole brain.

Studies in laboratory animals (minipigs, rodents, and dogs) have demonstrated the occurrence of cardiac arrhythmias and sudden death (with histologic evidence of myocardial necrosis) when beta-agonists and methylxanthines are administered concurrently. The clinical significance of these findings is unknown.

Pharmacokinetics:

Albuterol is rapidly absorbed after oral administration of 10 mL of Albuterol sulfate syrup (oral solution) (4 mg of Albuterol) in normal volunteers. Maximum plasma concentrations of about 18 ng/mL of Albuterol are achieved within 2 hours, and the drug is eliminated with a half-life of about 5 hours.

In other studies, the analysis of urine samples of patients given 8 mg of tritiated Albuterol orally showed that 76% of the dose was excreted over three days, with the majority of the dose being excreted within the first 24 hours. Sixty percent of this radioactivity was shown to be the metabolite. Feces collected over this period contained 4% of the administered dose.

Clinical Trials:

In controlled clinical trials in patients with asthma, the onset of improvement in pulmonary function, as measured by maximum midexpiratory flow rate (MMEF) and forced expiratory volume in 1 second (FEV1), was within 30 minutes after a dose of Albuterol sulfate syrup (oral solution), with peak improvement occurring between 2 and 3 hours. In a controlled clinical trial involving 55 children, clinically significant improvement (defined as maintaining a 15% or more increase in FEV1 and a 20% or more increase in MMEF over baseline values) continued to be recorded up to 6 hours. No decrease in the effectiveness was reported in one uncontrolled study of 32 children who took Albuterol sulfate syrup (oral solution) for a 3-month period.

Indications and Usage for Albuterol

Albuterol sulfate syrup (oral solution) is indicated for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease.

Contraindications

Albuterol sulfate syrup (oral solution) is contraindicated in patients with a history of hypersensitivity to Albuterol or any of its components.

Warnings

Cardiovascular Effects:

Albuterol sulfate syrup (oral solution), like all other beta-adrenergic agonists, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of Albuterol sulfate syrup (oral solution) at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiogram (ECG) changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Therefore, Albuterol sulfate syrup (oral solution), like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Deterioration of Asthma:

Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of Albuterol sulfate syrup (oral solution) than usual, this may be a marker of destabilization of asthma and requires re-evaluation of the patient and treatment regimen, giving special consideration to the possible need for anti-inflammatory treatment, e.g., corticosteroids.

Paradoxical Bronchospasm:

Albuterol sulfate syrup (oral solution) can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs, Albuterol sulfate syrup (oral solution) should be discontinued immediately and alternative therapy instituted.

Use of Anti-Inflammatory Agents:

The use of beta-adrenergic agonist bronchodilators alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids.

Immediate Hypersensitivity Reactions:

Immediate hypersensitivity reactions may occur after administration of Albuterol, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, and oropharyngeal edema. Albuterol, like other beta-adrenergic agonists, can produce a significant cardiovascular effect in some patients, as measured by pulse rate, blood pressure, symptoms, and/or electrocardiographic changes.

Rarely, erythema multiforme and Stevens-Johnson syndrome have been associated with the administration of Albuterol sulfate in children.

Precautions

General.

Albuterol, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines. Clinically significant changes in systolic and diastolic blood pressure have been seen in individual patients and could be expected to occur in some patients after use of any beta-adrenergic bronchodilator.

Large doses of intravenous Albuterol have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis. As with other beta-agonists, Albuterol may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.

Information for Patients:

The action of Albuterol sulfate syrup (oral solution) may last up to 6 hours or longer. Albuterol sulfate syrup (oral solution) should not be taken more frequently than recommended. Do not increase the dose or frequency of Albuterol sulfate syrup (oral solution) without consulting your physician. If you find that treatment with Albuterol sulfate syrup (oral solution) becomes less effective for symptomatic relief, your symptoms get worse, and/or you need to take the product more frequently than usual, you should seek medical attention immediately. While you are taking Albuterol sulfate syrup (oral solution), other asthma medications and inhaled drugs should be taken only as directed by your physician. Common adverse effects include palpitations, chest pain, rapid heart rate, and tremor or nervousness. If you are pregnant or nursing, contact your physician about the use of Albuterol sulfate syrup (oral solution). Effective and safe use of Albuterol sulfate syrup (oral solution) includes an understanding of the way that it should be administered.

Drug Interactions

The concomitant use of Albuterol sulfate syrup (oral solution) and other oral sympathomimetic agents is not recommended since such combined use may lead to deleterious cardiovascular effects. This recommendation does not preclude the judicious use of an aerosol bronchodilator of the adrenergic stimulant type in patients receiving Albuterol sulfate syrup (oral solution). Such concomitant use, however, should be individualized and not given on a routine basis. If regular coadministration is required, then alternative therapy should be considered.

Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of Albuterol on the vascular system may be potentiated.

Beta-Blockers: Beta-adrenergic receptor blocking agents not only block the pulmonary effect of beta-agonists, such as Albuterol sulfate syrup (oral solution), but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, e.g., as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

Diuretics: The ECG changes and/or hypokalemia that may result from the administration of nonpotassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of beta-agonists with nonpotassium-sparing diuretics.

Digoxin: Mean decreases of 16% to 22% in serum digoxin levels were demonstrated after single-dose intravenous and oral administration of Albuterol, respectively, to normal volunteers who had received digoxin for 10 days. The clinical significance of these findings for patients with obstructive airway disease who are receiving Albuterol and digoxin on a chronic basis is unclear. Nevertheless, it would be prudent to carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and Albuterol.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 2-year study in Sprague-Dawley rats, Albuterol sulfate caused a significant dose-related increase in the incidence of benign leiomyomas of the mesovarium at dietary doses of 2, 10, and 50 mg/kg (approximately ½, 2, and 10 times, respectively, the maximum recommended daily oral dose for adults and children on a mg/m2 basis). In another study this effect was blocked by the coadministration of propranolol, a non-selective beta-adrenergic antagonist. In an 18-month study in CD-1 mice Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 500 mg/kg (approximately 60 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis). In a 22-month study in the Golden hamster Albuterol sulfate showed no evidence of tumorigenicity at dietary doses of up to 50 mg/kg (approximately 8 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis).

Albuterol sulfate was not mutagenic in the Ames test with or without metabolic activation using tester strains S. typhimurium  TA1537, TA1538, and TA98 or E. coli  WP2, WPuvrA, and WP67. No forward mutation was seen in yeast strain S. cerevisiae  S9 nor any mitotic gene conversion in yeast strain S. cerevisiae  JD1 with or without metabolic activation. Fluctuation assays in S. typhimurium  TA98 and E. coli  WP2, both with metabolic activation, were negative. Albuterol sulfate was not clastogenic in a human peripheral lymphocyte assay or in an AH1 strain mouse micronucleus assay at intraperitoneal doses of up to 200 mg/kg.

Reproduction studies in rats demonstrated no evidence of impaired fertility at oral doses up to 50 mg/kg (approximately 15 times the maximum recommended daily oral dose for adults on a mg/m2 basis).

Pregnancy

Teratogenic Effects:  Pregnancy Category C:

Albuterol has been shown to be teratogenic in mice. A study in CD-1 mice at subcutaneous (sc) doses of 0.025, 0.25, and 2.5 mg/kg (approximately 3/1000, 3/100, and 3/10, respectively, the maximum recommended daily oral dose for adults on a mg/m2 basis), showed cleft palate formation in 5 of 111 (4.5%) fetuses at 0.25 mg/kg and in 10 of 108 (9.3%) fetuses at 2.5 mg/kg. The drug did not induce cleft palate formation at the lowest dose, 0.025 mg/kg. Cleft palate also occurred in 22 of 72 (30.5%) fetuses from females treated with 2.5 mg/kg of isoproterenol (positive control) subcutaneously (approximately 3/10 times the maximum recommended daily oral dose for adults on a mg/m2 basis).

A reproduction study in Stride Dutch rabbits revealed cranioschisis in 7 of 19 (37%) fetuses when Albuterol was administered orally at a 50 mg/kg dose (approximately 25 times the maximum recommended daily oral dose for adults on a mg/m2 basis).

There are no adequate and well-controlled studies in pregnant women. Albuterol should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

During worldwide marketing experience, various congenital anomalies, including cleft palate and limb defects, have been rarely reported in the offspring of patients being treated with Albuterol. Some of the mothers were taking multiple medications during their pregnancies. No consistent pattern of defects can be discerned, and a relationship between Albuterol use and congenital anomalies has not been established.

Use in Labor and Delivery:

Because of the potential for beta-agonist interference with uterine contractility, use of Albuterol sulfate syrup (oral solution) for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk.

Tocolysis: Albuterol has not been approved for the management of preterm labor. The benefit:risk ratio when Albuterol is administered for tocolysis has not been established. Serious adverse reactions, including maternal pulmonary edema, have been reported during or following treatment of premature labor with beta2-agonists, including Albuterol.

Nursing Mothers:

It is not known whether this drug is excreted in human milk. Because of the potential for tumorigenicity shown for Albuterol in some animal studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use:

Safety and effectiveness in children below 2 years of age have not been established.

Adverse Reactions

In clinical trials, the most frequent adverse reactions to Albuterol sulfate syrup (oral solution) in adults and older children were:

Percent Incidence of Adverse Reactions in Adults and Children (6-14 Years of Age)
Reaction Percent Incidence
Central nervous system
   Tremor 10% 
   Nervousness 9% 
   Shakiness 9% 
   Headache 4% 
   Dizziness 3% 
   Hyperactivity 2% 
   Excitement 2% 
   Sleeplessness 1% 
   Disturbed sleep <1% 
   Irritable behavior <1% 
   Dilated pupils <1% 
   Weakness <1% 
 
Cardiovascular
   Tachycardia 1% 
   Palpitations <1% 
   Sweating <1% 
   Chest pain <1% 
 
Ear, nose, and throat
   Epistaxis 1% 
 
Gastrointestinal
   Increased appetite 3% 
   Epigastric pain <1% 
   Stomachache <1% 
 
Musculoskeletal
   Muscle spasm <1% 
 
Respiratory
   Cough <1% 

In clinical trials, the following adverse reactions to Albuterol sulfate syrup (oral solution) were noted more frequently in young children 2 to 6 years of age than in older children and adults:

Percent Incidence of Adverse Reactions Noted More Frequently in Children 2 to 6 Years of Age Than in Older Children and Adults
Reaction Percent Incidence
Central nervous system
   Excitement 20% 
   Nervousness 15% 
   Hyperkinesia 4% 
   Sleeplessness 2% 
   Emotion lability 1% 
   Fatigue 1% 
 
Cardiovascular
   Tachycardia 2% 
   Pallor 1% 
 
Gastrointestinal
   Gastrointestinal symptoms 2% 
   Loss of appetite 1% 
 
Ophthalmolologic
   Conjuctivitis 1% 

Cases of urticaria, angioedema, rash, bronchospasm, hoarseness, oropharyngeal edema, and arrhythmias (including atrial fibrillation, supraventricular tachycardia, extrasystoles) have been reported after the use of Albuterol sulfate syrup (oral solution).

In addition, Albuterol, like other sympathomimetic agents, can cause adverse reactions such as hypertension, angina, vomiting, vertigo, central nervous system stimulation, unusual taste, and drying or irritation of the oropharynx.

The reactions are generally transient in nature, and it is usually not necessary to discontinue treatment with Albuterol sulfate syrup (oral solution). In selected cases, however, dosage may be reduced temporarily; after the reaction has subsided, dosage should be increased in small increments to the optimal dosage.

Overdosage

The expected symptoms with overdosage are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the symptoms listed under ADVERSE REACTIONS, e.g., seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats per minute, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, and sleeplessness. Hypokalemia may also occur. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of Albuterol sulfate syrup (oral solution). Treatment consists of discontinuation of Albuterol sulfate syrup (oral solution) together with appropriate symptomatic therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of Albuterol sulfate syrup (oral solution).

The oral median lethal dose of Albuterol sulfate in mice is greater than 2000 mg/kg (approximately 240 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis). In mature rats the subcutaneous (sc) median lethal dose of Albuterol sulfate is approximately 450 mg/kg (approximately 110 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis). In small young rats the oral median lethal dose is approximately 2000 mg/kg (approximately 480 times the maximum recommended daily oral dose for adults and children on a mg/m2 basis).

Albuterol Dosage and Administration

The following dosages of Albuterol sulfate syrup (oral solution) are expressed in terms of Albuterol base.

Usual Dosage:

Adults and Children Over 14 Years of Age: The usual starting dosage for adults and children over 14 years of age is 2 mg (1 teaspoonful) or 4 mg (2 teaspoonfuls) three or four times a day.

Children Over 6 Years to 14 Years of Age: The usual starting dosage for children over 6 years to 14 years of age is 2 mg (1 teaspoonful) three or four times a day.

Children 2 to 5 Years of Age: Dosing in children 2 to 5 years of age should be initiated at 0.1 mg/kg of body weight three times a day. This starting dosage should not exceed 2 mg (1 teaspoonful) three times a day.

Dosage Adjustment:

Adults and Children Over 14 Years of Age: For adults and children over 14 years of age, a dosage above 4 mg four times a day should be used only when the patient fails to respond. If a favorable response does not occur with the 4-mg initial dosage, it should be cautiously increased stepwise up to a maximum of 8 mg four times a day as tolerated.

Children Over 6 Years to 14 Years of Age Who Fail to Respond to the Initial Starting Dosage of 2 mg Four Times a Day: For children over 6 years to 14 years of age who fail to respond to the initial starting dosage of 2 mg four times a day, the dosage may be cautiously increased stepwise, but not to exceed 24 mg/day (given in divided doses).

Children 2 to 5 Years of Age Who Do Not Respond Satisfactorily to the Initial Dosage: For children from 2 to 5 years of age who do not respond satisfactorily to the initial starting dosage the dosage may be increased stepwise to 0.2 mg/kg of body weight three times a day, but not to exceed a maximum of 4 mg (2 teaspoonfuls) given three times a day.

Elderly Patients and Those Sensitive to Beta-Adrenergic Stimulators: The initial dosage should be restricted to 2 mg three or four times a day and individually adjusted thereafter.

How is Albuterol Supplied

Albuterol Sulfate Syrup (Oral Solution), a clear, orange liquid with a strawberry flavor, contains 2 mg of Albuterol (present as the sulfate) per 5 mL in bottles of 16 fluid ounces (one pint).

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Dispense contents with a child-resistant closure (as required) and in a tight, light-resistant container as defined in the USP/NF.

Manufactured by:
VINTAGE PHARMACEUTICALS, LLC
Huntsville, AL 35811

8182035
R12/06-R0


Albuterol Sulfate (Albuterol Sulfate)
PRODUCT INFO
Product Code 0254-9029 Dosage Form SOLUTION
Route Of Administration ORAL DEA Schedule
INGREDIENTS
Name (Active Moiety) Type Strength
Albuterol sulfate (Albuterol) Active 2 MILLIGRAM  In 5 MILLILITER
citric acid Inactive  
FD&C Yellow #6 Inactive  
hypromellose Inactive  
water Inactive  
saccharin sodium Inactive  
sodium benzoate Inactive  
sodium citrate Inactive  
strawberry flavor Inactive  
IMPRINT INFORMATION
Characteristic Appearance Characteristic Appearance
Color Score
Shape Symbol
Imprint Code Coating
Size
PACKAGING
# NDC Package Description Multilevel Packaging
1 0254-9029-58 473 MILLILITER In 1 BOTTLE None

Revised: 03/2007





Where can I get more information about Albuterol oral solution Albuterol Syrup ? We recommend to use www.Drugs.com

Typical mistypes for Albuterol oral solution Albuterol Syrup
zlbuterol oral solution albuterol syrup, slbuterol oral solution albuterol syrup, wlbuterol oral solution albuterol syrup, qlbuterol oral solution albuterol syrup, akbuterol oral solution albuterol syrup, apbuterol oral solution albuterol syrup, aobuterol oral solution albuterol syrup, alvuterol oral solution albuterol syrup, alnuterol oral solution albuterol syrup, alhuterol oral solution albuterol syrup, alguterol oral solution albuterol syrup, albyterol oral solution albuterol syrup, albhterol oral solution albuterol syrup, albjterol oral solution albuterol syrup, albiterol oral solution albuterol syrup, alb8terol oral solution albuterol syrup, alb7terol oral solution albuterol syrup, alburerol oral solution albuterol syrup, albuferol oral solution albuterol syrup, albugerol oral solution albuterol syrup, albuyerol oral solution albuterol syrup, albu6erol oral solution albuterol syrup, albu5erol oral solution albuterol syrup, albutwrol oral solution albuterol syrup, albutsrol oral solution albuterol syrup, albutdrol oral solution albuterol syrup, albutrrol oral solution albuterol syrup, albut4rol oral solution albuterol syrup, albut3rol oral solution albuterol syrup, albuteeol oral solution albuterol syrup, albutedol oral solution albuterol syrup, albutefol oral solution albuterol syrup, albutetol oral solution albuterol syrup, albute5ol oral solution albuterol syrup, albute4ol oral solution albuterol syrup, albuteril oral solution albuterol syrup, albuterkl oral solution albuterol syrup, albuterll oral solution albuterol syrup, albuterpl oral solution albuterol syrup, albuter0l oral solution albuterol syrup, albuter9l oral solution albuterol syrup, albuterok oral solution albuterol syrup, albuterop oral solution albuterol syrup, albuteroo oral solution albuterol syrup, albuterol iral solution albuterol syrup, albuterol kral solution albuterol syrup, albuterol lral solution albuterol syrup, albuterol pral solution albuterol syrup, albuterol 0ral solution albuterol syrup, albuterol 9ral solution albuterol syrup, albuterol oeal solution albuterol syrup, albuterol odal solution albuterol syrup, albuterol ofal solution albuterol syrup, albuterol otal solution albuterol syrup, albuterol o5al solution albuterol syrup, albuterol o4al solution albuterol syrup, albuterol orzl solution albuterol syrup, albuterol orsl solution albuterol syrup, albuterol orwl solution albuterol syrup, albuterol orql solution albuterol syrup, albuterol orak solution albuterol syrup, albuterol orap solution albuterol syrup, albuterol orao solution albuterol syrup, albuterol oral aolution albuterol syrup, albuterol oral zolution albuterol syrup, albuterol oral xolution albuterol syrup, albuterol oral dolution albuterol syrup, albuterol oral eolution albuterol syrup, albuterol oral wolution albuterol syrup, albuterol oral silution albuterol syrup, albuterol oral sklution albuterol syrup, albuterol oral sllution albuterol syrup, albuterol oral splution albuterol syrup, albuterol oral s0lution albuterol syrup, albuterol oral s9lution albuterol syrup, albuterol oral sokution albuterol syrup, albuterol oral sopution albuterol syrup, albuterol oral sooution albuterol syrup, albuterol oral solytion albuterol syrup, albuterol oral solhtion albuterol syrup, albuterol oral soljtion albuterol syrup, albuterol oral solition albuterol syrup, albuterol oral sol8tion albuterol syrup, albuterol oral sol7tion albuterol syrup, albuterol oral solurion albuterol syrup, albuterol oral solufion albuterol syrup, albuterol oral solugion albuterol syrup, albuterol oral soluyion albuterol syrup, albuterol oral solu6ion albuterol syrup, albuterol oral solu5ion albuterol syrup, albuterol oral solutuon albuterol syrup, albuterol oral solutjon albuterol syrup, albuterol oral solutkon albuterol syrup, albuterol oral solutoon albuterol syrup, albuterol oral solut9on albuterol syrup, albuterol oral solut8on albuterol syrup, albuterol oral solutiin albuterol syrup, albuterol oral solutikn albuterol syrup, albuterol oral solutiln albuterol syrup, albuterol oral solutipn albuterol syrup, albuterol oral soluti0n albuterol syrup, albuterol oral soluti9n albuterol syrup, albuterol oral solutiob albuterol syrup, albuterol oral solutiom albuterol syrup, albuterol oral solutioj albuterol syrup, albuterol oral solutioh albuterol syrup, albuterol oral solution zlbuterol syrup, albuterol oral solution slbuterol syrup, albuterol oral solution wlbuterol syrup, albuterol oral solution qlbuterol syrup, albuterol oral solution akbuterol syrup, albuterol oral solution apbuterol syrup, albuterol oral solution aobuterol syrup, albuterol oral solution alvuterol syrup, albuterol oral solution alnuterol syrup, albuterol oral solution alhuterol syrup, albuterol oral solution alguterol syrup, albuterol oral solution albyterol syrup, albuterol oral solution albhterol syrup, albuterol oral solution albjterol syrup, albuterol oral solution albiterol syrup, albuterol oral solution alb8terol syrup, albuterol oral solution alb7terol syrup, albuterol oral solution alburerol syrup, albuterol oral solution albuferol syrup, albuterol oral solution albugerol syrup, albuterol oral solution albuyerol syrup, albuterol oral solution albu6erol syrup, albuterol oral solution albu5erol syrup, albuterol oral solution albutwrol syrup, albuterol oral solution albutsrol syrup, albuterol oral solution albutdrol syrup, albuterol oral solution albutrrol syrup, albuterol oral solution albut4rol syrup, albuterol oral solution albut3rol syrup, albuterol oral solution albuteeol syrup, albuterol oral solution albutedol syrup, albuterol oral solution albutefol syrup, albuterol oral solution albutetol syrup, albuterol oral solution albute5ol syrup, albuterol oral solution albute4ol syrup, albuterol oral solution albuteril syrup, albuterol oral solution albuterkl syrup, albuterol oral solution albuterll syrup, albuterol oral solution albuterpl syrup, albuterol oral solution albuter0l syrup, albuterol oral solution albuter9l syrup, albuterol oral solution albuterok syrup, albuterol oral solution albuterop syrup, albuterol oral solution albuteroo syrup, albuterol oral solution albuterol ayrup, albuterol oral solution albuterol zyrup, albuterol oral solution albuterol xyrup, albuterol oral solution albuterol dyrup, albuterol oral solution albuterol eyrup, albuterol oral solution albuterol wyrup, albuterol oral solution albuterol strup, albuterol oral solution albuterol sgrup, albuterol oral solution albuterol shrup, albuterol oral solution albuterol surup, albuterol oral solution albuterol s7rup, albuterol oral solution albuterol s6rup, albuterol oral solution albuterol syeup, albuterol oral solution albuterol sydup, albuterol oral solution albuterol syfup, albuterol oral solution albuterol sytup, albuterol oral solution albuterol sy5up, albuterol oral solution albuterol sy4up, albuterol oral solution albuterol syryp, albuterol oral solution albuterol syrhp, albuterol oral solution albuterol syrjp, albuterol oral solution albuterol syrip, albuterol oral solution albuterol syr8p, albuterol oral solution albuterol syr7p, albuterol oral solution albuterol syruo, albuterol oral solution albuterol syrul, albuterol oral solution albuterol syru-, albuterol oral solution albuterol syru0, lbuterol oral solution albuterol syrup, abuterol oral solution albuterol syrup, aluterol oral solution albuterol syrup, albterol oral solution albuterol syrup, albuerol oral solution albuterol syrup, albutrol oral solution albuterol syrup, albuteol oral solution albuterol syrup, albuterl oral solution albuterol syrup, albutero oral solution albuterol syrup, albuteroloral solution albuterol syrup, albuterol ral solution albuterol syrup, albuterol oal solution albuterol syrup, albuterol orl solution albuterol syrup, albuterol ora solution albuterol syrup, albuterol oralsolution albuterol syrup, albuterol oral olution albuterol syrup, albuterol oral slution albuterol syrup, albuterol oral soution albuterol syrup, albuterol oral soltion albuterol syrup, albuterol oral soluion albuterol syrup, albuterol oral soluton albuterol syrup, albuterol oral solutin albuterol syrup, albuterol oral solutio albuterol syrup, albuterol oral solution albuterol syrup, albuterol oral solution albuterol syrup, albuterol oral solution lbuterol syrup, albuterol oral solution abuterol syrup, albuterol oral solution aluterol syrup, albuterol oral solution albterol syrup, albuterol oral solution albuerol syrup, albuterol oral solution albutrol syrup, albuterol oral solution albuteol syrup, albuterol oral solution albuterl syrup, albuterol oral solution albutero syrup, albuterol oral solution albuterolsyrup, albuterol oral solution albuterol yrup, albuterol oral solution albuterol srup, albuterol oral solution albuterol syup, albuterol oral solution albuterol syrp, albuterol oral solution albuterol syru, labuterol oral solution albuterol syrup, abluterol oral solution albuterol syrup, alubterol oral solution albuterol syrup, albtuerol oral solution albuterol syrup, albuetrol oral solution albuterol syrup, albutreol oral solution albuterol syrup, albuteorl oral solution albuterol syrup, albuterlo oral solution albuterol syrup, albutero loral solution albuterol syrup, albuterolo ral solution albuterol syrup, albuterol roal solution albuterol syrup, albuterol oarl solution albuterol syrup, albuterol orla solution albuterol syrup, albuterol ora lsolution albuterol syrup, albuterol orals olution albuterol syrup, albuterol oral oslution albuterol syrup, albuterol oral sloution albuterol syrup, albuterol oral soultion albuterol syrup, albuterol oral soltuion albuterol syrup, albuterol oral soluiton albuterol syrup, albuterol oral solutoin albuterol syrup, albuterol oral solutino albuterol syrup, albuterol oral solutio n albuterol syrup, albuterol oral solution albuterol syrup, albuterol oral solution a lbuterol syrup, albuterol oral solution labuterol syrup, albuterol oral solution abluterol syrup, albuterol oral solution alubterol syrup, albuterol oral solution albtuerol syrup, albuterol oral solution albuetrol syrup, albuterol oral solution albutreol syrup, albuterol oral solution albuteorl syrup, albuterol oral solution albuterlo syrup, albuterol oral solution albutero lsyrup, albuterol oral solution albuterols yrup, albuterol oral solution albuterol ysrup, albuterol oral solution albuterol sryup, albuterol oral solution albuterol syurp, albuterol oral solution albuterol syrpu, aalbuterol oral solution albuterol syrup, allbuterol oral solution albuterol syrup, albbuterol oral solution albuterol syrup, albuuterol oral solution albuterol syrup, albutterol oral solution albuterol syrup, albuteerol oral solution albuterol syrup, albuterrol oral solution albuterol syrup, albuterool oral solution albuterol syrup, albuteroll oral solution albuterol syrup, albuterol oral solution albuterol syrup, albuterol ooral solution albuterol syrup, albuterol orral solution albuterol syrup, albuterol oraal solution albuterol syrup, albuterol orall solution albuterol syrup, albuterol oral solution albuterol syrup, albuterol oral ssolution albuterol syrup, albuterol oral soolution albuterol syrup, albuterol oral sollution albuterol syrup, albuterol oral soluution albuterol syrup, albuterol oral soluttion albuterol syrup, albuterol oral solutiion albuterol syrup, albuterol oral solutioon albuterol syrup, albuterol oral solutionn albuterol syrup, albuterol oral solution albuterol syrup, albuterol oral solution albuterol syrup, albuterol oral solution aalbuterol syrup, albuterol oral solution allbuterol syrup, albuterol oral solution albbuterol syrup, albuterol oral solution albuuterol syrup, albuterol oral solution albutterol syrup, albuterol oral solution albuteerol syrup, albuterol oral solution albuterrol syrup, albuterol oral solution albuterool syrup, albuterol oral solution albuteroll syrup, albuterol oral solution albuterol syrup, albuterol oral solution albuterol ssyrup, albuterol oral solution albuterol syyrup, albuterol oral solution albuterol syrrup, albuterol oral solution albuterol syruup, albuterol oral solution albuterol syrupp, etc.



© Copyright by drug-information.ru 2001-2019. All rights reserved